Molecular characterization of radical prostatectomy specimens after systemic therapy may
identify a gene expression profile for resistance to therapy. This study assessed tumor cells …

Docetaxel is a standard chemotherapy for patients with metastatic prostate cancer. However,
the response is rather limited and not all of the patients benefit from this treatment. To …

Docetaxel is the main treatment for advanced castration‐resistant prostate cancer; however,
resistance eventually occurs. The development of intratumoral drug‐resistant …

The role of the androgen receptor (AR) signaling axis in the progression of prostate cancer
is a cornerstone to our understanding of the molecular mechanisms causing castration …

One of the factors promoting tumoral progress is the abnormal activation of the epithelial–
mesenchymal transition (EMT) program which has been associated with chemoresistance in …

Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant
survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the …

Simple Summary Therapeutic options for the treatment of men with metastatic castration-
resistant prostate cancer are limited. Docetaxel—a taxane-based chemotherapeutic agent …

Docetaxel remains the standard-of-care for men diagnosed with metastatic castrate-resistant
prostate cancer (CRPC). However, only approximately 50% of patients benefit from …

Background This study investigates the docetaxel-resistant mechanism and explores the
effect of tea polyphenols (TP) on autophagy and its related mechanism in human castration …

The ability of a population of PC3 prostate epithelial cancer cells to become resistant to
docetaxel therapy and progress to a mesenchymal state remains a fundamental problem …